{"id":975961,"date":"2026-06-25T16:19:15","date_gmt":"2026-06-25T20:19:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/"},"modified":"2026-06-25T16:19:15","modified_gmt":"2026-06-25T20:19:15","slug":"eikon-therapeutics-to-join-the-russell-3000-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/","title":{"rendered":"Eikon Therapeutics to Join the Russell 3000\u00ae Index"},"content":{"rendered":"<h2>\nAddition reflects Eikon&#8217;s progress as a publicly traded company and increasing visibility within the investment community<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>MILLBRAE, Calif., June  25, 2026  (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000<sup>\u00ae<\/sup> Index following the annual reconstitution, effective after the US market closes on June 26, 2026.<\/p>\n<p>The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth\/value\/defensive\/dynamic). The Russell 3000 Index measures the performance of approximately 3,000 stocks, designed to represent 98% of the investable US equity market, and includes large-cap, mid-cap and small-cap US equities. Like all Russell Indexes, the Russell 3000 is fully reconstituted each year in June (and will be subject to semi-annual reconstitution beginning in December 2026) to ensure accurate reflection of the targeted market segment.<\/p>\n<p>\n        <strong>About Eikon Therapeutics<\/strong><br \/>\n        <br \/>Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon\u2019s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon\u2019s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jQTA9HK-N6cx7vfYUoJosHejfxbu0VKlJZfkT33jaQ7ci1lbSciytuhF4WhVpb0nCCt0CTSm56x5zK4Ex2jkRRqsdpLfT-X1tetSy_yWGjU=\" rel=\"nofollow\" target=\"_blank\">www.eikontx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking\/Safe Harbor Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon\u2019s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon\u2019s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.<\/p>\n<p>These forward-looking statements are based upon management\u2019s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption \u201cRisk Factors\u201d and elsewhere in Eikon\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on May 11, 2026, and in other public filings with the SEC in the future.<\/p>\n<p>As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Alfred \u201cFreddie\u201d Bowie, Ph.D., CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qDzhrzCxcfIO6qEnZ03tM4gF-vjv-05Q9RRaRN-8WuDbac9sdYL66LgKP7pPBRvbv9jpwGvd_iFeM_Z3e_pFbg==\" rel=\"nofollow\" target=\"_blank\">ir@eikontx.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Colin Sanford<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fTivL39WmZOTMRwHdOLy3KTHwylM6XXahJ84OQJWYp2JoNby8S8QQvBp_y8dTm3tYtlpQwEy1DXDKZ197QAQocFXNBdqXgTIMWTdNol2lZk=\" rel=\"nofollow\" target=\"_blank\">colin@bioscribe.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjBlMWQ2NTctOGI4ZC00M2U0LWIzNjItMTM2NzFjNGFiN2RhLTEzMTk2NDMtMjAyNi0wNi0yNS1lbg==\/tiny\/Eikon-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Addition reflects Eikon&#8217;s progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000\u00ae Index following the annual reconstitution, effective after the US market closes on June 26, 2026. The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth\/value\/defensive\/dynamic). The Russell 3000 Index measures the performance of approximately 3,000 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eikon Therapeutics to Join the Russell 3000\u00ae Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-975961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Addition reflects Eikon&#8217;s progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000\u00ae Index following the annual reconstitution, effective after the US market closes on June 26, 2026. The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth\/value\/defensive\/dynamic). The Russell 3000 Index measures the performance of approximately 3,000 &hellip; Continue reading &quot;Eikon Therapeutics to Join the Russell 3000\u00ae Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-25T20:19:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eikon Therapeutics to Join the Russell 3000\u00ae Index\",\"datePublished\":\"2026-06-25T20:19:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/\",\"name\":\"Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\",\"datePublished\":\"2026-06-25T20:19:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-join-the-russell-3000-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eikon Therapeutics to Join the Russell 3000\u00ae Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/","og_locale":"en_US","og_type":"article","og_title":"Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk","og_description":"Addition reflects Eikon&#8217;s progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000\u00ae Index following the annual reconstitution, effective after the US market closes on June 26, 2026. The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth\/value\/defensive\/dynamic). The Russell 3000 Index measures the performance of approximately 3,000 &hellip; Continue reading \"Eikon Therapeutics to Join the Russell 3000\u00ae Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-25T20:19:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eikon Therapeutics to Join the Russell 3000\u00ae Index","datePublished":"2026-06-25T20:19:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/"},"wordCount":695,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/","name":"Eikon Therapeutics to Join the Russell 3000\u00ae Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=","datePublished":"2026-06-25T20:19:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjg1NiM3Njc5MTIxIzIzMDgwOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-join-the-russell-3000-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eikon Therapeutics to Join the Russell 3000\u00ae Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/975961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=975961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/975961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=975961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=975961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=975961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}